This company listing is no longer active
Jacobio Pharmaceuticals Group Past Earnings Performance
Past criteria checks 0/6
Jacobio Pharmaceuticals Group has been growing earnings at an average annual rate of 16.4%, while the Biotechs industry saw earnings growing at 11% annually. Revenues have been declining at an average rate of 38.5% per year.
Key information
16.4%
Earnings growth rate
39.7%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | -38.5% |
| Return on equity | -32.5% |
| Net Margin | -504.1% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Jacobio Pharmaceuticals Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 81 | -410 | 43 | 468 |
| 31 Mar 23 | 89 | -391 | 43 | 457 |
| 31 Dec 22 | 96 | -372 | 43 | 446 |
| 30 Sep 22 | 123 | -332 | 46 | 391 |
| 30 Jun 22 | 150 | -292 | 49 | 336 |
| 31 Mar 22 | 151 | -297 | 47 | 308 |
| 31 Dec 21 | 153 | -301 | 45 | 281 |
| 30 Sep 21 | 348 | -570 | 52 | 259 |
| 30 Jun 21 | 544 | -839 | 60 | 237 |
| 31 Mar 21 | 515 | -1,177 | 57 | 211 |
| 31 Dec 20 | 486 | -1,514 | 54 | 186 |
| 30 Sep 20 | 243 | -1,298 | 65 | 171 |
| 30 Jun 20 | 0 | -1,082 | 77 | 156 |
| 31 Mar 20 | 0 | -753 | 74 | 147 |
| 31 Dec 19 | 0 | -425 | 71 | 139 |
Quality Earnings: 1167 is currently unprofitable.
Growing Profit Margin: 1167 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1167 is unprofitable, but has reduced losses over the past 5 years at a rate of 16.4% per year.
Accelerating Growth: Unable to compare 1167's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1167 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 1167 has a negative Return on Equity (-32.49%), as it is currently unprofitable.